Mathini Ilancheran

Mathini Ilancheran


  • Use Of Wearable And Sensor Applications In Clinical Trials Is Booming

    Experts predict 50% of clinical trials will incorporate wearables and sensors by 2025, compared to the 10 to 15% at present. This article shares market research on the use of wearables and sensors in clinical trials, including smartwatches, ingestible sensor-embedded pills, and more.

  • Decentralized Trials: Trends & Technology Propelling Home Healthcare Services

    Moving some trial site activities into patients’ homes has been shown to increase recruitment by 60% or more, and it typically maintains patient retention at over 90%. This article delves into research regarding trends and technology enabling decentralized trials.

  • The Asia-Pacific Region: A Hot Spot For Clinical Trials

    The Asia-Pacific region has become the hot spot for conducting clinical trials. Why? There is an ease of regulatory compliance, a low cost of conducting studies, a growing patient population, and the presence of a few top clinical institutions acting as sites.

  • COVID-19’s Impact On The Clinical Trial Ancillary Supplies Industry

    With restrictions on logistics, and countries implementing new restrictions to address increasing COVID-19 cases, it’s important to understand how to manage clinical trials’ ancillary supplies — like sourcing from the right suppliers, managing distribution to all trial sites, stock management, and response to new regulations.

  • Analyzing The Top Clinical Trial Technology Trends

    Technology plays a critical role in drug development and the R&D value chain by revolutionizing clinical trials and decreasing the failure rate. Though the supply of technology has been increasing and regulation of innovative methods is easing, pharmaceutical companies have been slow to use the emerging technologies, due to the ambiguity prevailing around this space and a highly fragmented supply market. This article outlines the key technologies that have a high impact across trial phases.

  • Digital Platforms For Patient Engagement In Clinical Trials — Trends & Outlook

    Pharmaceutical companies have three targeted users: physicians, pharmacists, and patients. Various digital platforms are used to create a good customer experience for educating these end users. The core focus is on patients driving patient care, education, and adherence.

  • An Introduction To Financial Benchmarking In Biopharma Clinical Development

    The high cost and failure rate of new drug candidates going through clinical trials are well documented and a recurring subject of research both by industry and academia.1 Further, the cost of drug development is a debated topic, and there is no consensus on what the “true cost” is because of the different methods used for these calculations.2 The lack of adequate comparable cost data and value measures also makes it difficult for pharmaceutical sponsors and trial sites to implement financial benchmarking for planning, costing, and budget management.

  • An Analysis Of Clinical Development Benchmarking Practices

    Pharma companies use performance and competitive benchmarking to identify opportunities during their drug development cycle. The benchmarks are aimed at finding ways to make improvements in cost savings, lead time reduction (faster drug to market), and quality of services.

  • Analyzing The Top Clinical Trial Outsourcing Trends Of 2017

    In 2017, clinical development services did not witness any significant changes in terms of price index, input cost, and supply-demand gap in comparison to 2016. However, market competition increased, with the supply market seeing continuous mergers and acquisitions, resulting in consolidation and CROs competing for market share in terms of enhanced therapeutic area expertise, geographic reach, full-service capability, technology, and increased functional capability. 

  • Measuring The Impact Of Reforms On India’s Clinical Trial Environment

    The clinical trial environment in India has seen a downward trend since 2013, when the government approached the Supreme Court regarding the death of 2,644 volunteers during clinical trials over seven years.